A Comprehensive Approach to Head and Neck Cancer Prehabilitation

Overview

Head and neck cancer accounts for 3% of malignancies in the United States. However, the diagnosis and treatment for head and neck cancer is considered to be debilitating. Not because of its morbidity, but due to the extremely rigorous treatment course which has a profound impact on patients physical, social, and emotional functioning. Disfigurement and sensorimotor deficits further compound this impact. Head and neck cancer patients contend with treatments that can significantly affect their quality of life. Treatment regularly results in decreased functional capacity and decreased quality of life. Physical impairments are manifested through, but not limited to, disfigurement, deconditioning, communication issues, "swallowing, speech, breathing, and cancer-related fatigue". Premorbid factors such as preexisting anxiety and depression, chemical dependency, financial barriers, and lack of social support system are unique obstacles to the head and neck cancer population impacting treatment and outcomes. Due to these factors, patients experience higher rates of anxiety and depression, psychological distress, and fear of cancer recurrence. In fact, "compared with other survivors of cancer, head and neck cancer survivors are almost 2 times more likely to die from suicide". In view of the aforementioned research, Roger Maris Cancer Center's head and neck cancer will implement a prehabilitation program that evaluates each patient using standardized screening tools and provide personalized education and interventions. This project evaluates a more comprehensive and proactive multidisciplinary approach to improve treatment and outcomes in head and neck cancer patients.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2024

Interventions

  • Other: Prehabilitation Program
    • We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.

Arms, Groups and Cohorts

  • Active Comparator: Prospective Prehabilitation
    • Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
  • No Intervention: Prospective Control
    • Prospectively enrolling patients to a control arm with no intervention.

Clinical Trial Outcome Measures

Primary Measures

  • Difference between treatment and control group, from baseline in the BHS-6 to after treatment.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; and 6-months follow-up
    • The Behavioral Health Screening 6 (BHS-6) is a validated, self-report instrument assessing psychological health. Higher scores indicate greater psychological distress. Difference = (Treatment score – Control score).
  • Difference between treatment and control group, from baseline in the C-SSRS to after treatment.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; and 6-months follow-up
    • The Columbia-Suicide Severity Rating Scale (C-SSRS) is a validated, self-report instrument assessing suicidality. Higher scores indicate greater suicidality. Difference = (Treatment score – Control score).
  • Difference between treatment and control group, from baseline in the NCCN Distress Thermometer after treatment.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; and 6-months follow-up
    • The National Comprehensive Cancer Network (NCCN) Distress Thermometer is a validated, self-report instrument assessing psychological health. Higher scores indicate greater psychological distress. Difference = (Treatment score – Control score).
  • Difference between treatment and control group, from baseline in the MDADI to after treatment.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; and 6-months follow-up
    • The MD Anderson Dysphagia Inventory (MDADI) is a validated, self-report instrument of functional assessments of dysphasia and overall functioning. Higher scores indicate better quality of life and higher day-to-day functioning. Difference = (Treatment score – Control score).
  • Difference between treatment and control group, from baseline in the FACT-H&N (Version 4) to after treatment.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; and 6-months follow-up
    • The FACT-H&N (Version 4) is a validated, self-report instrument of functional assessments of dysphasia and overall functioning. Higher scores indicate better quality of life and higher day-to-day functioning. Difference = (Treatment score – Control score).

Secondary Measures

  • Impact of sarcopenia on functioning
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months
    • Sarcopenia will be measured using bioimpedence spectroscopy technology (BIS), a validated noninvasive measure of volume of fluids in various parts of the body. Functional assessments (sit to stand, grip strength, and two-minute walk test) will be tested as possible predictors of sarcopenia.
  • Difference between treatment and control group on sarcopenia measures
    • Time Frame: Post-treatment, ranging from 2 weeks to 6 months
    • Sarcopenia measures collected via computed tomography will be used to compare patients who completed the prehabilitation program and those who have not.
  • Change from baseline to after treatment on the BHS-6.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The Behavioral Health Screening 6 (BHS-6) is a validated self-report measure of psychological health, with higher scores indicating greater psychological distress. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the C-SSRS.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The Columbia-Suicide Severity Rating Scale (C-SSRS) is a validated self-report measure of psychological health, with higher scores indicating greater psychological distress. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the NCCN Distress Thermometer.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The National Comprehensive Cancer Network (NCCN) Distress Thermometer is a validated self-report measure of psychological health, with higher scores indicating greater psychological distress. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the 2-min walk test.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The 2-min walk test is a validated objective measure of physical functioning. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the 30 seconds sit to stand.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The 30 seconds sit to stand is a validated objective measure of physical functioning. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the grip strength.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The grip strength is a validated objective measure of physical functioning. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the NFPE.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The Nutrition Focused Physical Exam (NFPE) is a validated objective measure of physical functioning. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the MDADI.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The MD Anderson Dysphagia Inventory (MDADI) is a validated, self-report instrument of functional assessments of dysphasia and overall functioning. Higher scores indicate better quality of life and higher day-to-day functioning. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the BIS.
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The Bioelectic impedance spectroscopy (BIS) is a validated objective measure of physical functioning. Change = (Post-treatment score – Baseline score).
  • Change from baseline to after treatment on the FACT-H&N (Version 4).
    • Time Frame: Baseline; post-treatment, ranging from 2 weeks to 6 months; 6 months follow-up
    • The FACT-H&N (Version 4) is a validated, self-report instrument of functional assessments of overall functioning. Higher scores indicate better quality of life and higher day-to-day functioning. Change = (Post-treatment score – Baseline score).

Participating in This Clinical Trial

Inclusion Criteria

  • Equal to or greater than 18 years of age – Diagnosis of head and neck cancer – Actively pursuing cancer treatment with a curative intent – Willing and able to provide written consent Exclusion Criteria:

  • Patients with cardiac arrhythmia with implanted pacemaker – Patients with other implanted electronic equipment/device – Patients undergoing external defibrillation – Pregnant women (per BIS instructions for use, pregnant women should not participate) – Patient weight exceeding 375 lbs. – Patient has a metal allergy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sanford Health
  • Collaborator
    • University of North Dakota
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Cheryl Hysjulien, PsyD, Principal Investigator, Sanford Health

References

Samuel SR, Maiya AG, Fernandes DJ, Guddattu V, Saxena PUP, Kurian JR, Lin PJ, Mustian KM. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer. 2019 Oct;27(10):3913-3920. doi: 10.1007/s00520-019-04750-z. Epub 2019 Mar 27.

Stenson, K. M. (2019). Epidemiology and risk factors for head and neck cancer. UpToDate. Retrieved, November 15, 2019 from https://www.uptodate.com/contents/epidemiology-and-risk-factors-for-head-and-neck-cancer.

Osazuwa-Peters N, Simpson MC, Zhao L, Boakye EA, Olomukoro SI, Deshields T, Loux TM, Varvares MA, Schootman M. Suicide risk among cancer survivors: Head and neck versus other cancers. Cancer. 2018 Oct 15;124(20):4072-4079. doi: 10.1002/cncr.31675. Epub 2018 Oct 18.

Beck ACC, Passchier E, Retel VP, Stuiver MM, van der Molen L, Klop WMC, Navran A, van Harten WH, van den Brekel MWM. Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy. BMC Cancer. 2019 Jul 3;19(1):655. doi: 10.1186/s12885-019-5874-z.

Jung AR, Roh JL, Kim JS, Kim SB, Choi SH, Nam SY, Kim SY. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. Eur J Cancer. 2019 Jul;116:98-106. doi: 10.1016/j.ejca.2019.05.006. Epub 2019 Jun 10.

Barrett-Bernstein M, Carli F, Gamsa A, Scheede-Bergdahl C, Minnella E, Ramanakumar AV, Tourian L. Depression and functional status in colorectal cancer patients awaiting surgery: Impact of a multimodal prehabilitation program. Health Psychol. 2019 Oct;38(10):900-909. doi: 10.1037/hea0000781. Epub 2019 Aug 5.

Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, Goepfert H. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6.

D'Antonio LL, Zimmerman GJ, Cella DF, Long SA. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1996 May;122(5):482-7. doi: 10.1001/archotol.1996.01890170018005.

List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer. 1996 Jun 1;77(11):2294-301. doi: 10.1002/(SICI)1097-0142(19960601)77:113.0.CO;2-S.

Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE, Carli F. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA Surg. 2018 Dec 1;153(12):1081-1089. doi: 10.1001/jamasurg.2018.1645.

Mordarski BA, Hand RK, Wolff J, Steiber AL. Increased Knowledge, Self-Reported Comfort, and Malnutrition Diagnosis and Reimbursement as a Result of the Nutrition-Focused Physical Exam Hands-On Training Workshop. J Acad Nutr Diet. 2017 Nov;117(11):1822-1828. doi: 10.1016/j.jand.2017.06.362. Epub 2017 Aug 16. No abstract available.

Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.

Sealy MJ, Dechaphunkul T, van der Schans CP, Krijnen WP, Roodenburg JLN, Walker J, Jager-Wittenaar H, Baracos VE. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clin Nutr. 2020 Feb;39(2):501-509. doi: 10.1016/j.clnu.2019.02.029. Epub 2019 Feb 22.

Wall LR, Ward EC, Cartmill B, Hill AJ. Physiological changes to the swallowing mechanism following (chemo)radiotherapy for head and neck cancer: a systematic review. Dysphagia. 2013 Dec;28(4):481-493. doi: 10.1007/s00455-013-9491-8.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.